COLMYC-E Injectable 10%

Quốc gia: Malaysia

Ngôn ngữ: Tiếng Anh

Nguồn: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Thành phần hoạt chất:

ENROFLOXACIN

Sẵn có từ:

Laboratorios Reveex (asia) Sdn. Bhd.

INN (Tên quốc tế):

ENROFLOXACIN

Các đơn vị trong gói:

100.00 mcg/mL

Sản xuất bởi:

S.P. Veterinaria, S.A.

Đặc tính sản phẩm

For veterinary use only
COLMYC-E INJ 10%
INJECTABLE SOLUTION
F.E VENTURE SDN BHD
Lot 3 & 5 , Jalan Pjs 11/8
Bandar Sunway 46150 Petaling Jaya
Selangor Darul Ehsan – MALAYSIA
Phone: [phone]
Fax: [phone]
Distributed by:
Manufactured by:
Registration Holder:
LABORATORIOS REVEEX ASIA SDN BHD
Lot 3 & 5 , Jalan Pjs 11/8
Bandar Sunway 46150 Petaling Jaya
Selangor Darul Ehsan – MALAYSIA
Phone: [phone] - Fax: [phone]
COMPOSITION
Enrofloxacin .............................
10 g.
Excipient to .............................. 100 ml.
PHARMACODYNAMIC PROPERTIES
Enrofloxacin
is
bactericidal
in
action
with activity against a wide range of
Gram
positive
and
Gram
negative
bacteria
and
mycoplasmas.
The
mechanism of action of the quinolones
is unique among antimicrobials - they
act primarily to inhibit bacterial DNA
gyrase,
an
enzyme
responsible
for
controlling the supercoiling of bacterial
DNA during replication. Resealing of
the double stranded helix is inhibited
resulting in irreversible degradation of
the
chromosomal
DNA.
The
fluoroquinolones
also
possess
activity
against bacteria in the stationary phase
by an alteration of the permeability of
the outer membrane phospholipid cell
wall.
Molecular resistance to fluoroquinolones
has been observed to arise from two
principal sources, (i) alteration to DNA
gyrase
or
topoisomerase
IV
and
(ii)
alterations in drug permeability of the
bacterial cell. Both mechanisms lead to a
reduced susceptibility of the bacteria to
fluoroquinolones.
Clinical
resistance
is
dependent
on
several
mutations
accumulating in a step-wise manner.
PHARMACOKINETIC PROPERTIES
The
pharmacokinetics
of
enrofloxacin
are
such
that
oral
and
parenteral
administration
leads
to
similar
serum
levels. Enrofloxacin possesses a high
distribution volume. Tissue levels 2-3
higher than that found in the serum,
have been demonstrated in laboratory
animals and target species. Organs in
which high levels can be expected are
the lungs, liver, kidney, skin, bone and
lymphatic
system.
Enrofloxacin
also